Quantitative analysis of estrogen receptor heterogeneity in breast cancer

被引:84
作者
Chung, Gina G.
Zerkowski, Maciej P.
Ghosh, Sriparna
Camp, Robert L.
Rimm, David L.
机构
[1] Yale Univ, Ctr Canc, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA
关键词
breast cancer; estrogen receptor; tumor heterogeneity; automated analysis; quantitative analysis;
D O I
10.1038/labinvest.3700543
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Immunohistochemical analyses (IHC) of biomarkers are extensively used for tumor characterization and as prognostic and predictive measures. The current standard of single slide analysis assumes that one 5 mM section is representative of the entire tumor. We used our automated image analysis technology (AQUA) using a modified IHC technique with fluorophores to compare estrogen receptor (ER) expression in multiple blocks/slides from cases of primary breast cancer with the objective of quantifying tumor heterogeneity within sections and between blocks. To normalize our ER scores and allow slide-to-slide comparisons, 0.6 mu m histospots of representative breast cancer cases with known ER scores were assembled into a 'gold standard array' (GSA) and placed adjacently to each whole section. Overall, there was excellent correlation between AQUA scores and the pathologist's scores and reproducibility of GSA scores (mean linear regression R value 0.8903). Twenty-nine slides from 11 surgical cases were then analyzed totaling over 2000 AQUA images. Using standard binary assignments of AQUA (> 10) and pathologist's (> 10%) scores as being positive, there was fair concordancy between AQUA and pathologist scores (73%) and between slides from different blocks from the same cases (75%). However using continuous AQUA scores, agreement between AQUA and pathologist was far lower and between slides from different blocks from the same cases only 19%. Within individual slides there was also significant heterogeneity in a scattered pattern, most notably for slides with the highest AQUA scores. In sum, using a quantitative measure of ER expression, significant block-to-block heterogeneity was found in 81% of cases. These results most likely reflect both laboratory-based variability due to lack of standardization of immunohistochemistry and true biological heterogeneity. It is also likely to be dependent on the biomarker analyzed and suggests further studies should be carried out to determine how these findings may affect clinical decision-making processes.
引用
收藏
页码:662 / 669
页数:8
相关论文
共 27 条
[1]  
ALLRED DC, 1990, ARCH SURG-CHICAGO, V125, P107
[2]   Estrogen responsiveness and control of normal human breast proliferation [J].
Anderson, E ;
Clarke, RB ;
Howell, A .
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 1998, 3 (01) :23-35
[3]   X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization [J].
Camp, RL ;
Dolled-Filhart, M ;
Rimm, DL .
CLINICAL CANCER RESEARCH, 2004, 10 (21) :7252-7259
[4]  
Camp RL, 2003, CANCER RES, V63, P1445
[5]   Automated subcellular localization and quantification of protein expression in tissue microarrays [J].
Camp, RL ;
Chung, GG ;
Rimm, DL .
NATURE MEDICINE, 2002, 8 (11) :1323-1327
[6]   Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray [J].
Chung, GG ;
Yoon, HH ;
Zerkowski, MP ;
Ghosh, S ;
Thomas, L ;
Harigopal, M ;
Charette, LA ;
Salem, RR ;
Camp, RL ;
Rimm, DL ;
Burtness, BA .
CANCER, 2006, 106 (08) :1677-1684
[7]  
Clarke M, 1998, LANCET, V351, P1451
[8]   RECEPTOR HETEROGENEITY OF HUMAN-BREAST CANCER AS MEASURED BY MULTIPLE INTRATUMORAL ASSAYS OF ESTROGEN AND PROGESTERONE-RECEPTOR [J].
DAVIS, BW ;
ZAVA, DT ;
LOCHER, GW ;
GOLDHIRSCH, A ;
HARTMANN, WH .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1984, 20 (03) :375-382
[9]   Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma [J].
Douglas-Jones, AG ;
Collett, N ;
Morgan, JM ;
Jasani, B .
JOURNAL OF CLINICAL PATHOLOGY, 2001, 54 (12) :951-955
[10]   Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:: Evidence from a phase III randomized trial [J].
Ellis, MJ ;
Coop, A ;
Singh, B ;
Mauriac, L ;
Llombert-Cussac, A ;
Jänicke, F ;
Miller, WR ;
Evans, DB ;
Dugan, M ;
Brady, C ;
Quebe-Fehling, E ;
Borgs, M .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) :3808-3816